Apnimed Q2: FDA Accepts Oxnimbi NDA with Feb 2027 PDUFA Date; $125.9M Net Income
APMD sits 29% above its 52-week low of $22.35.
Summary
Apnimed reported Q2 2026 net income of $125.9 million, driven by one-time gains, and announced FDA acceptance of its Oxnimbi NDA with a PDUFA date of February 28, 2027. The company also secured a $150 million credit facility and monetized its Shionogi interest for $100 million upfront.
Key Events · Earnings and Guidance · APMD
-
FDA Accepts Oxnimbi NDA
FDA accepted the NDA for AD109 (proposed name Oxnimbi) for obstructive sleep apnea and assigned a PDUFA target action date of February 28, 2027.
-
Q2 Net Income $125.9M
Net income of $125.9 million for Q2 2026, driven by an $85.4 million gain on sale of equity method investment and a $57.1 million gain on reversal of deposit liability — both non-recurring items.
-
$150M Credit Facility Secured
Completed a senior secured credit facility for up to $150 million with funds managed by HealthCare Royalty Partners to support commercial readiness.
-
$100M Shionogi Monetization
Monetized its interest in Shionogi-Apnimed Sleep Science for $100 million in upfront proceeds, with potential for additional milestone and royalty payments.
Analysis · APMD · Life Sciences
Apnimed's Q2 earnings release carries two major developments beyond the headline net income figure. The FDA accepted the NDA for AD109 (Oxnimbi) and set a PDUFA target action date of February 28, 2027 — a concrete regulatory milestone that de-risks the path to potential first-in-class oral OSA therapy approval. The company also disclosed a $150 million senior secured credit facility with HealthCare Royalty Partners and a $100 million upfront monetization of its Shionogi-Apnimed Sleep Science interest, materially strengthening its balance sheet ahead of a potential commercial launch. The $125.9 million net income is largely non-operational, driven by an $85.4 million gain on sale of equity method investment and a $57.1 million gain on reversal of deposit liability — not recurring revenue. Investors should focus on the regulatory timeline and cash runway rather than the headline profit.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.8% of the 1618 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, APMD was trading at $28.79 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $22.35 to $35.29. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.